Biotron Limited news
The Directors are pleased to advise that Biotron Limited (‘Biotron’ or ‘the Company’) has received guidance from the U.S. Food and Drug Administrations (‘FDA’) for development of its lead antiviral drug BIT225 as a potential treatment of Coronavirus Disease 2019 (COVID-19) infection in adults.
The FDA’s guidance was received in written response to Biotron’s pre-IND briefing package and request in March 2022, which included an overview of
The Directors are pleased to advise that the Company’s lead clinical drug, BIT225, has demonstrated effective protection from severe disease in mice with established SARS-CoV-2 infection in a new animal study performed at The SCRIPPS Research Institute, La Jolla, CA, USA.
- In a significant step forward, new data shows that BIT225 protects from severe disease even when started once there is an established infectio
During the quarter ended 31 March 2022 Biotron Limited (‘Biotron’ or ‘the Company’) achieved key outcomes including:
- Confirmed and extended previous findings on the effectiveness of Biotron`s lead antiviral drug BIT225 against SARS-CoV-2 in an animal model of human COVID-19 through demonstration of 100% survival despite administration of a lethal dose of the virus.
- Submitted a